Latest Tumors Stories
Alex's Lemonade Stand Foundation Supports Cancer Vaccine Research at the University of Maryland. COLLEGE PARK, Md., Jan.
A protein that has been at the center of cancer drug design for the last 20 years should not be given up on according to new research from the University of East Anglia (UEA).
A deadly, rare type of soft-tissue cancer may be completely eradicated simply by inhibiting a key protein involved in its growth.
Drugs that enhance a process called oxidative stress were found to kill rhabdomyosarcoma tumor cells growing in the laboratory and possibly bolstered the effectiveness of chemotherapy against this aggressive tumor of muscle and other soft tissue.
Three and a half years after beginning a clinical trial which demonstrated the first successful and sustained use of genetically engineered T cells to fight leukemia, a research team from the Perelman School of Medicine at the University of Pennsylvania and the Children's Hospital of Philadelphia will today announce the latest results of studies involving both adults and children with advanced blood cancers that have failed to respond to standard therapies.
A Ludwig Cancer Research study has uncovered an entirely novel mechanism by which glioblastoma (GBM), the most common kind of brain cancer, evades targeted therapies.
Researchers from UCLA's Jonsson Comprehensive Cancer Center led an international team of scientists in conducting two studies that provide critical insights into two important ways that tumors resist BRAF inhibitors.